AIM
MDGL icon

Aigen Investment Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Aigen Investment Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-881
Closed -$461K – 703
2026
Q1 		$461K Sell
881
-1,771
-67% -$846K 0.12% 232
2025
Q4 		$1.54M Buy
2,652
+2,067
+353% +$1.06M 0.36% 68
2025
Q3 		$268K Buy
+585
New +$218K 0.04% 571
2025
Q1 		– Sell
-1,771
Closed -$546K – 913
2024
Q4 		$546K Buy
+1,771
New +$498K 0.1% 308
2023
Q3 		– Sell
-2,270
Closed -$524K – 977
2023
Q2 		$524K Sell
2,270
-862
-28% -$233K 0.08% 340
2023
Q1 		$759K Buy
+3,132
New +$853K 0.1% 231
2020
Q4 		– Sell
-1,759
Closed -$209K – 931
2020
Q3 		$209K Buy
+1,759
New +$191K 0.03% 634

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Aigen Investment Management's MDGL Position: Q2 2026 in Review

Aigen Investment Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 881 shares — an estimated $461K sold.

Aigen Investment Management first reported a position in MDGL in Q3 2020 and held it in 7 quarters. The position peaked at $1.54M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Aigen Investment Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Aigen Investment Management sold 881 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $461K.
  • Aigen Investment Management first reported a position in Madrigal Pharmaceuticals in Q3 2020 and held it in 7 quarters.
  • Aigen Investment Management's Madrigal Pharmaceuticals position peaked at $1.54M in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Aigen Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.